People: Cleveland Biolabs Inc (CBLI.PH)

CBLI.PH on Philadelphia Stock Exchange

3.65USD
22 Jan 2016
Change (% chg)

-- (--)
Prev Close
$3.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
203
52-wk High
$6.93
52-wk Low
$2.41

Search Stocks

Summary

Name Age Since Current Position

Langdon Miller

60 2015 President and Chief Medical Officer

Yakov Kogan

41 2012 Chief Executive Officer, Director

C. Neil Lyons

58 2012 Chief Financial Officer

Andrei Gudkov

58 2003 Chief Scientific Officer, Director

Anna Evdokimova

2015 Director

Konstantin Gorshkov

2015 Director

Natalia Khudyk

2015 Director

Yulia Lebedina

36 2015 Director

Tatiana Levina

2015 Director

Ivan Persiyanov

35 2015 Director

Natalia Saraeva

2015 Director

James Antal

64 2006 Independent Director

Richard McGowan

61 2014 Independent Director

Anthony Principi

70 2013 Independent Director

Randy Saluck

49 2013 Independent Director

Rachel Levine

Vice President, Investor Relations

Biographies

Name Description

Langdon Miller

Dr. Langdon L. Miller, M.D., is President and Chief Medical Officer of Cleveland BioLabs, Inc. Dr. Miller has served as a strategic medical advisor to Cleveland BioLabs since February 2014. He has more than 20 years of experience in the design and conduct of translational and clinical drug development programs in oncology (both in hematological and solid tumors) and orphan diseases. Dr. Miller has worked in all phases of drug development, from first-in-human studies through pivotal registration-directed trials to medical affairs programs and has filed multiple Investigational New Drug applications, Clinical Trial Applications, New Drug Applications and orphan drug applications. He played major roles in the development of filgrastim and sargramostim, in the regulatory approvals of irinotecan, exemestane, epirubicin, dexrazoxane, sunitinib, and idelalisib in several cancers, and in validating new endpoints for Duchenne muscular dystrophy and cystic fibrosis. Dr. Miller has extensive experience in the generation, analysis, presentation, and justification of drug development programs before regulatory authorities, advisory committees, investigators, investors, and business development partners. He has authored over 100 regulatory documents and publications. Prior to establishing his consultancy in 2013, Dr. Miller held leadership positions in government and in large and small biopharmaceutical companies, including the National Cancer Institute, Pharmacia Corporation, PTC Therapeutics, Calistoga Pharmaceuticals, and Gilead Sciences. He holds a Doctorate of Medicine from Northwestern University and completed his residency in internal medicine at the University of Minnesota and an oncology fellowship at Stanford University.

Yakov Kogan

Dr. Yakov Kogan Ph.D., serves as Chief Executive Officer, Director of Cleveland BioLabs, Inc. Dr. Kogan has served as one of our directors since our inception in June 2003. Dr. Kogan has served as our Chief Executive Officer since June 2012. Previously, he served as our Chief Operating Officer from February 2008 until June 2012 and as our Interim Chief Executive Officer from January 2012 until June 2012. Dr. Kogan also served as our Executive Vice President of Business Development from our inception until February 2008. From 2002 to 2003, he was Director for Business Development at Integrated Genomics where he was responsible for commercial sales and expansion of the company’s capital base. Prior to his tenure in business development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics and ThermoGen, Inc. and as Research Associate at the University of Chicago. Dr. Kogan holds a Ph.D. degree in Molecular Biology from All-Union Research Institute of Genetics and Selection of Industrial Microorganisms (VNIIGenetika) (Moscow, Russia), as well as an MBA degree from the University of Chicago Graduate School of Business. Dr. Kogan’s day-to-day leadership as Chief Executive Officer provides our board with intimate knowledge of our operations.

C. Neil Lyons

Mr. C. Neil Lyons, CPA, is Chief Financial Officer of Cleveland BioLabs, Inc., since September 1, 2012. Mr. Lyons has over 30 years of experience related to operations, finance, SEC compliance, complex financial transactions, strategy, information systems and corporate governance. Prior to joining the Company, from April, 2005 until August, 2011, Mr. Lyons served as Chief Financial Officer and Treasurer of RegeneRx Biopharmaceuticals, Inc., where he led several financial transactions, identified and captured government grant opportunities, directed investor relations activities, developed financial models and implemented investment strategies and employee benefit programs. From 2003 until 2005, Mr. Lyons founded and was the principal of Ironbridge Consulting, a firm that provided financial consulting services, to businesses in the Washington, D.C. metro area. From 1998 until 2003, Mr. Lyons was the Vice President, Finance, for Alcatel’s SkyBridge Limited Partnership, an international satellite broadband start-up, where he secured significant amounts of capital and was an active participant in acquisition and joint venture activities. Prior to that, Mr. Lyons served in various positions at Bell Atlantic (now Verizon), from 1996 to 1998, Honeywell Federal Systems, Inc., a major Department of Defense contractor from 1990 to 1996, and practiced public accounting with Deloitte and Arthur Young from 1979 to 1990. Mr. Lyons is a certified public accountant and received a Bachelor of Science degree in accounting, magna cum laude, from Florida Southern College.

Andrei Gudkov

Dr. Andrei V. Gudkov, Ph.D., D.Sci., is Chief Scientific Officer, Director of Cleveland BioLabs, Inc., since June 2003. Since 2007, Dr. Gudkov has served as Senior Vice President of Basic Science and Chairman of the Department of Cell Stress Biology at Roswell Park Cancer Institute. From 2001 to 2007, he was Chairman of the Department of Molecular Biology at the Lerner Research Institute at the Cleveland Clinic and Professor of Biochemistry at Case Western Reserve University. Prior to this, he was a tenured faculty member in the Department of Molecular Genetics at the University of Illinois at Chicago, where his lab concentrated on the development of new functional gene discovery methodologies and the identification of new candidate cancer treatment targets. Before immigrating to the United States in 1990, Dr. Gudkov worked at The National Cancer Research Center in Moscow, where he led a broad research program focused on virology and cancer drug resistance. Dr. Gudkov holds a Ph.D. in Experimental Oncology from the Cancer Research Center (Moscow, Russia). Dr. Gudkov provides our board with invaluable insight into the scientific direction of the Company.

Anna Evdokimova

Ms. Anna Evdokimova is an Director of the Company. Ms. Evdokimova has served as Venture Capital Investment Director of Millhouse LLC, an asset management company, since May 2015 and served as the Deputy Head of Corporate Finance from 2006 to May 2015. She also currently serves on the board of directors of JSC Registrator “R.O.S.T.”, "Russia Forest Product", "MKM-Logistics", and "Anyclip Ltd". From 2002 to 2004, Ms. Evdokimova worked as the Head of Corporate Finance of major Russian oil and gas company Slavneft. In 1998 Ms. Evdokimova joined Russian listed oil major Sibneft and served as Head of Export Finance through 2002. Ms. Evdokimova holds a Bachelor’s degree from Moscow State Linguistic University and a Master’s of Business Administration in Finance from Fordham University.

Konstantin Gorshkov

Mr. Konstantin Gorshkov is an Director of Cleveland BioLabs, Inc. Mr. Gorshkov has served as Senior Manager of the Investment Projects Support Division at Millhouse LLC, an asset management company, since 2008. Prior to joining Millhouse, he was a lawyer with Global Wealth Management Center Limited from 2006 to 2008. From 2003 to 2006, Mr. Gorshkov served as legal counsel at Vedenie Specialnix Proektov LLC, SNS-Holding CJSC, and then Microtech Solution LLC. Mr. Gorshkov holds a law degree from Moscow State University.

Natalia Khudyk

Ms. Natalia Khudyk is an Director of the Company. Ms. Khudyk has served as the Head of Planning, Finance and Accounts at Millhouse LLC, an asset management company, since 2006. From 2002 to 2006, Ms. Khudyk worked at Millhouse Capital UK Ltd. as the UK Head of Finance and Accounts. Prior to joining Millhouse, she was Chief Executive Officer at ZAO “Pragma-Lux”. From 1999 to 2001, Ms. Khudyk was the Head of the Moscow office of Runicom Ltd. and from 1997 to 1999 she was Chief Executive Officer and Chief Financial Officer of the Moscow office of Runicom S.A. From 1994 to 1997, Ms. Khudyk worked as an accountant at the Moscow office of Glencore International AG and from 1992 to 1994 she held the position of Economist at Commercial Bank “Roscombank”. Ms. Khudyk holds a degree in economics, finance, and banking from the Financial Academy under The Government of the Russian Federation.

Yulia Lebedina

Ms. Yulia Lebedina is an Director of the Company. Ms. Lebedina has served as the Head of the Corporate Department at Millhouse, LLC, an asset management company, since 2008 and served as the Head of Legal project support from 2006 to 2008, where she provided corporate governance and legal support for several key transactions. Ms. Lebedina also currently serves on the board of directors of JSC Registrator “R.O.S.T.”, Zoltav Resources Inc. (LON:ZOL), and AO “Seaport Pevek”. Prior to joining Millhouse, she was Senior Corporate Counsel at major Russian oil company Sibneft. From 1999 to 2005, Ms. Lebedina held several positions as legal counsel at KPM Consulting, Stolitza, and ?PM Consulting Limited, where she provided legal counsel to Russian corporations. Ms. Lebedina holds both Bachelor’s and Master’s degrees in Law from the Peoples' Friendship University of Russia.

Tatiana Levina

Ms. Tatiana Levina is an Director of the Company. Ms. Levina has served as the Head of Financial Analysis and Reporting of Millhouse LLC, an asset management company, since 2008, where she supported several key transactions. From 2001 to 2006, she was an accountant specializing in International Financial Reporting Standards at TNK-BP Management OJSC. Ms. Levina holds a Master’s degree in economics from Plekhanov Russian Economic University in Moscow and an accounting degree from the Business College of Ben-Gurion University of the Negev in Israel.

Ivan Persiyanov

Mr. Ivan Persiyanov is an Director of the Company. Mr. Persiyanov has served as Investment Director of Millhouse LLC, an asset management company, since 2014. Mr. Persiyanov also currently serves on the board of directors of Propell Technologies Group Inc. (OTCBB:PROP), and Georezonans, LLC. From 2008 to 2014, Mr. Persiyanov was Investment Director at Rusnano, a multi-billion dollar investment fund, where he originated and led the execution of several key investments. Prior to this, he was a consultant with Ernst & Young and held management and risk analysis positions with GE Money Bank and Citibank. From 2013-2014, Mr. Persiyanov served on the board of directors of Optogan CJSC, Beneq OY, and LED-Microsensor NT LLC. He holds a mathematics degree from Moscow State University and a Master’s degree in finance from the New Economic School.

Natalia Saraeva

Ms. Natalia Saraeva is an Director of the Company. Ms. Saraeva has served as Senior Specialist of planning in the Finance and Reporting department of Millhouse LLC, an asset management company, since 2013. From 2007 to 2013, she was an auditor and then senior auditor with KPMG LLC in Russia. Ms. Saraeva holds a degree in economics with a specialization in accounting, analysis and audit from the Volga State Academy of Water Transportation.

James Antal

Mr. James J. Antal, CPA, is an Independent Director of Cleveland BioLabs, Inc., since July 20, 2006. Mr. Antal served as Chief Financial Officer of Experian Group Ltd. from 1996 to 2001 and as Chief Investment Officer from 2001 to 2002. Experian is a leading global provider of consumer and business credit information, direct marketing information services, and integrated customer relationship management processes. From 1997 to 2002, he also served on the board of directors of First American Real Estate Solutions, an Experian joint venture with First American Financial Corp. Starting in 2002, Mr. Antal served as an advisor to the board of directors for Plexus Vaccine, Inc., a biotech company, until it was acquired by SIGA Technologies in 2004. In December 2004, he joined the SIGA board of directors, and also currently serves on its audit and nominating and governance committees. From May 2004 to August 2005, he was engaged as the Chief Financial Advisor to the Black Mountain Gold Coffee Co. From July 2005 to August 2009, he served on a part-time basis as Chief Financial Officer of Pathway Data Inc., a privately-held company engaged in consumer credit notification and identity theft assistance services. Mr. Antal earned a Bachelor of Science degree in Business Administration with an Accounting major from the Ohio State University in 1973. He became a Certified Public Accountant (Ohio) in 1975. Mr. Antal’s experience in accounting and finance, particularly with respect to biotechnology companies and public reporting companies make him an important asset to our board and a qualified Audit Committee Chairman.

Richard McGowan

Mr. Richard S. McGowan, Esq., J.D., serves as an Independent Director of the company. Mr. McGowan has served as one of our directors since June 2014. The Board has nominated Mr. McGowan to serve as chairman effective following the 2015 Annual Meeting of Stockholders. Such nomination is contingent on his election to serve on the Board for the next term. Mr. McGowan has been admitted to the practice of law in the states of Connecticut, New York and Massachusetts and numerous Federal Courts for over 30 years, retiring from active practice in 2010. From 1985 to 2009, Mr. McGowan specialized on a national level in the prosecution of mass tort pharmaceutical drug, product liability, and class action cases where he served on several Lead Plaintiff Committees and as Class Counsel, first as a Partner at Rheingold & McGowan, P.C., and then while Of Counsel for Weitz & Luxenberg, P.C. From 2000 to 2008, he was also a partner and President of SFB Holdings, a private investment company that sought to purchase and turn around sub-producing micro-cap companies. Since 2008, he has been involved as a private investor in micro-cap companies. He was an Instructor with the Intensive Trial Advocacy Program at the Cardozo Law School from 1986 to 2001. Mr. McGowan received a Bachelor’s degree from the State University of New York at Stony Brook and a Juris Doctor degree from the University of Boston, School of Law. Mr. McGowan provides our board with stockholder perspective and in-depth legal expertise for both the pharmaceutical industry and micro-cap companies.

Anthony Principi

Mr. Anthony J. Principi, J.D., has been appointed as Independent Director of Cleveland BioLabs, Inc., effective April 22, 2013. Mr. Principi serves as principal of The Principi Group, a consulting firm. From March to May 2005 and from 2006 through 2010, he was Senior Vice President of Government Relations of Pfizer, Inc. Prior to joining Pfizer, Inc., Mr. Principi served as Secretary of the U.S. Department of Veterans Affairs from 2001 through 2005. In 2005, he served as the Chairman of the Defense 2005 Base Realignment and Closure Commission. Prior to becoming Secretary of the U.S. Department of Veterans Affairs, Mr. Principi was President of QTC Medical Services Inc. from 1999 through 2001 and Senior Vice President of Lockheed Martin IMS from 1995 through 1996. Prior to joining Lockheed Martin IMS, Mr. Principi was Chief Counsel and Staff Director of the U.S. Senate Armed Services Committee from 1993 through 1994, and was Chief Counsel and Staff Director of the U.S. Senate Committee on Veterans’ Affairs from 1984 through 1988. Mr. Principi serves as a director and member of the corporate governance and compensation and evaluation committees of Mutual of Omaha. He is also a member of the board of directors of Engility Holdings, Inc. and is a member of its compensation and nominating/corporate governance committees. Mr. Principi serves as a director of A. T. Kearney and Onsite Health, Inc. He served as Executive Chairman of QTC Management, and was a director of Perot Systems Corporation. Mr. Principi received a Bachelor of Science from the U.S. Naval Academy and a Juris Doctor from Seton Hall University School of Law. Mr. Principi provides our board with expertise in public health and government affairs.

Randy Saluck

Mr. Randy S. Saluck, J.D., MBA, has been appointed as Independent Director of Cleveland BioLabs, Inc., effective May 7, 2013. Mr. Saluck has been the Managing Member of Mortar Rock Capital Management, LLC and the Portfolio Manager of Mortar Rock Capital LP, a value-oriented investment fund, since 2005. From 2002 to 2005, Mr. Saluck was a portfolio manager at the investment fund of Meisenbach Capital, LP and, from 2000 to 2002, Mr. Saluck was a senior analyst at Tyndall Partners, LLC, which invested in value-oriented equities and distressed debt. From 1999 to 2000, Mr. Saluck was an analyst at Highfields Capital Management, LLC, where he was responsible for special situations and risk arbitrage. Prior thereto, Mr. Saluck was an investment banker focused on mergers and acquisitions involving a variety of industries at Salomon Brothers Inc. Before becoming an investment banker, Mr. Saluck was a corporate and securities attorney, working at Cahill Gordon & Reindel LLP and then Tenzer Greenblatt LLP. As an attorney, Mr. Saluck worked with numerous small capitalization companies assisting them in the execution of their financing and strategic plans. He received a Bachelor’s degree from the University of Pennsylvania, a Juris Doctor degree from the University of Virginia and an MBA from the Wharton School of the University of Pennsylvania with a concentration in finance and accounting. Mr. Saluck currently serves on the Board of Directors of the Connecticut Region of the Anti-Defamation League. Mr. Saluck provides our board with stockholder perspective and experience in public finance and investor relationships.

Rachel Levine

Search Stocks